Chronic Obstructive Pulmonary Disease Drugs Market to Witness an Outstanding Growth by 2025

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease which includes emphysema, chronic bronchitis, refractory asthma, and some forms of bronchiectasis. This disease is characterized by increasing breathlessness, wheezing, tightness in chest etc. In the early stages, there may be no symptoms but the symptoms gradually increases in later stages. Shortness of breath, chronic cough, fatigue, frequent flu, weight-loss etc. are the symptoms exhibited in the later stages. Spirometry, chest X-ray, arterial blood gas test etc. are the common tests for diagnosing COPD. Smoking, genetic factors and environmental pollution are some major risk factor that developed chronic obstructive pulmonary diseases.

Browse Full Research Report: https://www.transparencymarketresearch.com/chronic-obstructive-pulmonary-disease-drugs-market.html

Based on drug type, the chronic obstructive pulmonary diseases market can be segmented into anticholinergic, oral corticosteroid, beta2-agonists, phosphodiesterase-4 (PDE4) inhibitors and others (antibiotic, methylxanthines etc.). Among these, the oral corticosteroid segment is likely to expand significantly compare to other drugs owing to extensive uses in the treatment of all types of chronic obstructive pulmonary diseases. Based on test type, the chronic obstructive pulmonary diseases drugs market can be classified as lung functional test, chest x-ray test, CT scan, and others (arterial blood gas test, genetic test etc.). Among these, the lung functional test which is also called as spirometry test is expand at a high growth rate because, the test is convenient, and accurately measure the lung function and capacity. Based on application, the chronic obstructive pulmonary diseases drugs market can be classified into emphysema, chronic bronchitis, and refractory asthma. The chronic bronchitis segment is expand at a significant rate due to increasing prevalence’s of the disease and it provides effective and efficient treatment especially for the geriatric people. As per the Forum of International Respiratory Societies (FIRS), chronic obstructive pulmonary diseases affects more than 200 million individuals worldwide annually and is likewise considered as one of the main sources of death comprehensively.. Attributable to these disturbing measurements, the utilization of pulmonary drugs is probably going to pick up force, and thereby the market will also grow accordingly.. Moreover, the advent of combination drugs is further projected to propel the growth of the global chronic obstructive pulmonary diseases drugs market. However, unknown etiology of chronic obstructive pulmonary diseases in medical industry and lack of proper awareness about the effect of chronic obstructive pulmonary diseases would might hinder the growth of the market.

In terms of region, the global chronic obstructive pulmonary diseases drugs market can be segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominates global market followed by Europe due to growing use of the drugs for treatment of COPD and high awareness regarding treatment. Increasing environmental pollution, rapidly growing the number smoker’s and the growing prevalence’s of pulmonary disease are like to attribute the market of chronic obstructive pulmonary diseases drugs in Asia Pacific region. Advancements in drug delivery, increasing per capita income, rising expenditure on personal care and growing incidences of diseases especially chronic pulmonary diseases are likely to augment the market for chronic obstructive pulmonary diseases in Middle East & Africa region during the forecast period.

Major players operating in the global chronic obstructive pulmonary diseases market include., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Novartis AG, Bayer AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Actelion Pharmaceuticals, IncSunovion Pharmaceuticals, Inc. and others.